Evidence map›Paper›PMID 42782878›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Tumour GDF-15 Expression and Clinical Outcomes in Intermediate-Risk Metastatic Clear-Cell Renal Cell Carcinoma Treated with Second-Line Nivolumab.

Orhun Akdogan, Betul Ogut, Osman Sutcuoglu, Melike Urganci, Burcu Ulas Kahya, Ipek Isik Gonul, Hatice Azra Begum Salimoglu, Tuba Ugur Tuzcu, Ozan Yazici, Ahmet Ozet and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Orhun AkdoganDepartment of Medical Oncology, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey.ORCID 0000-0003-0212-1191
Betul OgutDepartment of Pathology, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey.
Osman SutcuogluDepartment of Medical Oncology, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey.
Melike UrganciDepartment of Pathology, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey.
Burcu Ulas KahyaDepartment of Medical Oncology, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey.
Ipek Isik GonulDepartment of Pathology, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey.
Hatice Azra Begum SalimogluDepartment of Internal Medicine, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey.ORCID 0009-0007-3492-8818
Tuba Ugur TuzcuDepartment of Medical Oncology, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey.
Ozan YaziciDepartment of Medical Oncology, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey.
Ahmet OzetDepartment of Medical Oncology, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey.
Nuriye OzdemirDepartment of Medical Oncology, Faculty of Medicine, Gazi University, 06560 Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, ImmunologicalCarcinoma, Renal CellGrowth Differentiation Factor 15Kidney NeoplasmsNivolumabAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeAntineoplastic Agents, ImmunologicalGDF15 protein, humanGrowth Differentiation Factor 15NivolumabcachexiaGDF-15immune checkpoint inhibitorimmunohistochemistrynivolumabrenal cell carcinomatissue biomarker

Identifiers

PMID42782878
PMCPMC13605094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.